RecruitingNCT05264051
MAsS Scan as a Predictor of Morbidity and Mortality in Patients With Liver Disease
Sponsor
University of Chicago
Enrollment
1,200 participants
Start Date
Apr 18, 2022
Study Type
OBSERVATIONAL
Conditions
Summary
The purpose of the study is to study the muscle assessment score (MAsS, utilizing MRI, as an objective measure of frailty and muscle composition to serve as a predictor of morbidity and mortality in patients with liver disease.
Eligibility
Min Age: 18 Years
Inclusion Criteria1
- Patients who are already scheduled for an MRI for routine clinical purposes will be evaluated
Exclusion Criteria1
- \<18 yrs. of age
Interested in this trial?
Get notified about updates and connect with the research team.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05264051
Related Trials
Veteran-Centered Care for Advanced Liver Disease (Vet-CALD)
NCT060684918 locations
Development of a FibroScan Liver Examination Using a Single Probe
NCT074002894 locations
Assessing Declined Liver Grafts With Normothermic Machine Perfusion to Reduce Transplant Waiting Time
NCT068742969 locations
Enhancing Alcohol Treatment Engagement in Associated Liver Disease (ALD) Patients
NCT062695101 location
RTX001 Autologous Engineered Macrophages for Liver Cirrhosis
NCT0682371314 locations